Drugs / s-adenosyl-methionine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00070941 | Jul 2003 → Jun 2010 | Parkinson disease, depressive disorder | NYU Langone Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | s-adenosyl-methionine | “This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).” NCT00070941 ↗ |
| Known as | SAM-e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00070941 ↗ |
| Route | Oral | “40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.” NCT00070941 ↗ |